• 中文名稱：

• 克唑替尼

• 中文別名：

• 克里唑替尼;

  克里唑啼尼;

  3-[(1R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(4-哌啶)-1H-吡唑-4-基]-2-吡啶胺;

  3-[(R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(哌啶-4-基)-1H-吡唑-4-基]吡啶-2-胺;

• 英文名稱：

• Crizotinib

• 英文別名：

• (R)-Crizotinib;

  3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine;

  Xalkori;

• CAS號(hào)：

• 877399-52-5

• 分子式：

• C21H22Cl2FN5O

• 分子量：

• 450.33700

• 精確質(zhì)量：

• 449.11900

• PSA：

• 77.99000

• LogP：

• 5.94770

Crizotinib (trade name Xalkori, Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children